24 completed. 24 Phase 1, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 24 | Completed 24 |
| Phase 2 | 11 | Completed 11 |
Follow Obsessive-Compulsive Disorder: new trials by email Literature Review of Obsessive-Compulsive Disorder trials Research Report on Obsessive-Compulsive Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective. Group A. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by anxiety disorders and depression., Group B. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by PTSD, Group C. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder. - Anxiety, Depression | Phase 1 | Completed | Rakitzi, Stavroula | 107 | 2025-06-02 | 2026-08-04 |
| Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD Psilocybin - Obsessive-Compulsive Disorder | Phase 1 | Completed | Centre for Addiction and Mental Health | 10 | 2024-09-01 | 2026-09-24 |
| PsilOCD: A Pharmacological-Challenge Feasibility Study Psilocybin (COMP360) - Obsessive-Compulsive Disorder | Phase 1 | Completed | Imperial College London | 19 | 2022-10-28 | 2024-11-06 |
| Self-control and Body-focused Repetitive Behaviors self-control - Trichotillomania (Hair-Pulling Disorder), Skin-Picking | Phase 1 | Completed | American University | 80 | 2020-06-30 | 2022-11-07 |
| Rituximab for Obsessive-compulsive Disorder. (RITS-PO-2019) Rituximab - Obsessive-Compulsive Disorder, Treatment Resistant Disorders | Phase 1 | Completed | Region Örebro County | 11 | 2019-08-08 | 2022-05-10 |
| Psilocybin for Treatment of Obsessive Compulsive Disorder Psilocybin 100 mcg/kg, Psilocybin 300 mcg/kg, Lorazepam 1 mg - Obsessive-compulsive Disorder (OCD) | Phase 1 | Completed | University of Arizona | 15 | 2019-01-02 | 2024-08-30 |
| Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study. Psilocybin (0.25mg/kg), Niacin (250mg) - Obsessive-Compulsive Disorder | Phase 1 | Completed | Yale University | 28 | 2018-11-13 | 2026-10-16 |
| Bioequivalence Study of Paroxetine Tablets and Paxil® Under Fasting and Fed Conditions in Chinese Healthy Volunteers Paroxetine Hydrochloride Tablet 20 mg, Paxil® 20 mg - Major Depressive Disorder, Obsessive-Compulsive Disorder | Phase 1 | Completed | Beijing Tongren Hospital | 53 | 2018-03-29 | 2018-12-19 |
| Effects of Marijuana on Symptoms of OCD Cannabis, Placebo - Obsessive-Compulsive Disorder | Phase 1 / Phase 2 | Completed | New York State Psychiatric Institute | 14 | 2017-10-01 | 2020-11-18 |
| The Modular Protocol for Mental Health (MPMH) The Modular Protocol for Mental Health, Treatment-as-usual - Major Depressive Disorder, Generalized Anxiety Disorder | Phase 1 / Phase 2 | Completed | Medical Research Council Cognition and Brain Sciences Unit | 43 | 2017-07-18 | 2020-09-29 |
| Cannabinoid Medication for Adults With OCD Nabilone, Exposure and Response Prevention Therapy - Obsessive-Compulsive Disorder | Phase 1 / Phase 2 | Completed | New York State Psychiatric Institute | 16 | 2016-09-01 | 2020-08-06 |
| Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD) Ketamine - Obsessive-Compulsive Disorder | Phase 1 / Phase 2 | Completed | New York State Psychiatric Institute | 5 | 2015-03-01 | 2020-08-17 |
| Brief Behavioral Treatment for Anxiety in Young Children Parent-Led Exposure Therapy, Treatment As Usual - Obsessive-compulsive Disorder, Social Phobia | Phase 1 / Phase 2 | Completed | University of South Florida | 58 | 2014-01-01 | 2016-10-06 |
| Attention Training for Childhood Obsessive Compulsive Disorder: An Open Case Series Attention Modification Program - Obsessive Compulsive Disorder | Phase 1 | Completed | University of California, Los Angeles | 6 | 2012-11-01 | 2017-01-16 |
| Computer Assisted Cognitive Behavior Therapy for Obsessive Compulsive Disorder: A Comprehensive Stepped-Care Approach Computer-Assisted Cognitive Behavior Therapy (BT STEPS) - Obsessive Compulsive Disorder | Phase 1 | Completed | Center for Psychological Consultation | 88 | 2012-01-01 | 2014-03-14 |
| Cognitive Behavioral Therapy (CBT) for Anxiety Disorders in Autism: Adapting Treatment for Adolescents Cognitive-Behavioral Therapy, Wait-list - Anxiety Disorders in Youth With Autism, Asperger's Syndrome, and Pervasive Developmental Disorder Not Otherwise Specified | Phase 1 / Phase 2 | Completed | University of South Florida | 33 | 2009-11-01 | 2014-07-01 |
| Cognitive Behavioral Therapy for Trichotillomania Cognitive Behavioral Therapy - Trichotillomania | Phase 1 / Phase 2 | Completed | Massachusetts General Hospital | 38 | 2008-11-01 | 2012-06-20 |
| Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project Cognitive-behavioral therapy, Wait-list control - Prader Willi Syndrome, Obsessive-compulsive Disorder | Phase 1 / Phase 2 | Completed | University of South Florida | 24 | 2008-09-01 | 2011-08-08 |
| Refining the Target for Deep Brain Stimulation (DBS) in Severe, Treatment Refractory Obsessive Compulsive Disorder (OCD) VC/VS stimulation - Obsessive-Compulsive Disorder | Phase 1 / Phase 2 | Completed | Universitaire Ziekenhuizen KU Leuven | 6 | 2008-03-01 | 2013-11-15 |
| Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors Pramipexole, Amisulpride - Obsessive-Compulsive Disorder | Phase 1 | Completed | GlaxoSmithKline | 52 | 2006-08-01 | 2014-09-15 |
Showing 20 of 24. Sign in to see all of them.
Anxiety Disorders (3) · Generalized Anxiety Disorder (3) · Phobia, Social (3) · Depressive Disorder, Major (2) · Panic Disorder (2) · Stress Disorders, Post-Traumatic (2) · Trichotillomania (2) · Agoraphobia (1) · Anxiety, Separation (1) · Asperger Syndrome (1) · Autistic Disorder (1) · Bipolar Disorder (1) · Compulsive Behavior (1) · Depression (1)
Mental Disorders (24) · Anxiety Disorders (21) · Behavior (3) · Mood Disorders (3) · Phobic Disorders (3) · Behavioral Symptoms (2) · Depressive Disorder (2) · Disruptive, Impulse Control, and Conduct Disorders (2) · Nervous System Diseases (2) · Neurobehavioral Manifestations (2) · Neurodevelopmental Disorders (2) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Stress Disorders, Traumatic (2)
Cognitive Behavioral Therapy (4) · Psilocybin (4) · Adenosine Monophosphate (1) · Amisulpride (1) · Behavior Therapy (1) · Deep Brain Stimulation (1) · Implosive Therapy (1) · Ketamine (1) · Lorazepam (1) · Memantine (1) · Mental Health (1) · Motivational Interviewing (1) · Niacin (1) · Paroxetine (1) · Pramipexole (1)
New York State Psychiatric Institute (4) · University of South Florida (3) · American University (1) · Beijing Tongren Hospital (1) · Boston University Charles River Campus (1) · Center for Psychological Consultation (1) · Centre for Addiction and Mental Health (1) · GlaxoSmithKline (1) · Imperial College London (1) · Marie-laure Welter (1) · Massachusetts General Hospital (1) · Medical Research Council Cognition and Brain Sciences Unit (1) · Rakitzi, Stavroula (1) · Region Örebro County (1) · Stanford University (1)
United States (15) · United Kingdom (3) · Belgium (1) · Canada (1) · China (1) · France (1) · Greece (1) · Sweden (1)
Benjamin Kelmendi, MD (1) · Dr David Erritzoe (1) · Dr Luca Pellegrini (1) · Dr. Polyxeni Georgila, M. D. (1) · Dr. Stavroula Rakitzi, PhD (1) · Eric Storch, Ph.D. (1) · Eric Storch, PhD (1) · Francisco A. Moreno, MD (1) · Gail Steketee (1) · Gwyneth Zai, MD, MSc, PhD (1) · Helen B Simpson, M.D., Ph.D. (1) · Helen Blair Simpson, MD, PhD (1) · James McCraken, MD (1) · John J Barry, MD (1)
PMID 17196053, PMID 19005196, PMID 19142108, PMID 20621362, PMID 20951978, PMID 21456040, PMID 23945445, PMID 25526831, PMID 30082367, PMID 34693989, PMID 37181888, PMID 39899368, PMID 41825921
K23MH122777 (1), R21MH068539 (1), R34HD065274 (1), R34MH071570 (1), R34MH095885 (1)